Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2009

Sigma-Aldrich Licenses Polyplus Transfection’s ZNA Oligos for Research Use

  • Sigma-Aldrich negotiated a worldwide license agreement to manufacture and commercialize Polyplus-transfection’s Zip Nucleic Acid (ZNA™) oligonucleotides for research applications. The company points out it will be the first to offer ZNA as custom DNA and RNA oligos to the life science industry.

    ZNA’s are oligonucleotides with attached cationic units. Polyplus claims the cationic residues increases the sensitivity of the oligos and results in increased affinity for nucleic acids without the loss of selectivity. Research applications of ZNAs include their use as PCR probes and primers, for in vitro miRNA detection and inhibition, and for siRNA applications.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »